lonigutamab
lonigutamab: developed by 2 companies · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (2)
| Company | Phase |
|---|---|
| ALUMIS INC. (ALMS) | Phase 1/Phase 2 |
| ACELYRIN, Inc. (SLRN) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
FDA Decisions
FDA_MeetingThe Company gained alignment on the proposed LONGITUDE-1 and LONGITUDE-2 Phase 3 trial designs.(SLRN)
Frequently asked questions
Who is developing lonigutamab?
lonigutamab is being developed by ALUMIS INC., ACELYRIN, Inc..
How many clinical trials involve lonigutamab?
BioSniper tracks 1 clinical trial involving lonigutamab.
What is lonigutamab's latest FDA decision?
The most recent tracked FDA decision for lonigutamab is FDA_Meeting for The Company gained alignment on the proposed LONGITUDE-1 and LONGITUDE-2 Phase 3 trial designs..
Get deeper analysis on lonigutamab
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis